Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-22-643
Abstract: Background Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI), has proven efficacy as the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, there is no standard effective second-line treatment option following progression on lenvatinib… read more here.
Keywords: plus lenvatinib; patients unresectable; antibodies plus; treatment ... See more keywords